Newsroom

Newsroom

Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study

Literature
Read More

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Literature
Read More

A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)

Literature
Read More

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial

Literature
Read More

Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Literature
Read More

Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer

Literature
Read More

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

Press Release
Read More

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Press Release
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients